Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $505.7 million.

  • Axsome Therapeutics' Total Non-Current Liabilities rose 3114.09% to $505.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.7 million, marking a year-over-year increase of 3114.09%. This contributed to the annual value of $419.8 million for FY2024, which is 2958.52% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Total Non-Current Liabilities of $505.7 million as of Q3 2025, which was up 3114.09% from $487.1 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Total Non-Current Liabilities ranged from a high of $505.7 million in Q3 2025 and a low of $136.0 million during Q2 2022
  • Over the past 4 years, Axsome Therapeutics' median Total Non-Current Liabilities value was $327.8 million (recorded in 2023), while the average stood at $329.3 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first soared by 12005.12% in 2023, then soared by 2553.0% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Total Non-Current Liabilities stood at $190.8 million in 2022, then surged by 69.77% to $324.0 million in 2023, then grew by 29.59% to $419.8 million in 2024, then grew by 20.45% to $505.7 million in 2025.
  • Its last three reported values are $505.7 million in Q3 2025, $487.1 million for Q2 2025, and $452.9 million during Q1 2025.